When is it Cool to Drool? Oral Fluid Testing for Controlled Substance Monitoring - Insights
PACE / State of FLThis webinar will describe substance use disorders and the common laboratory tests and matrices used for controlled substance monitoring. The advantages and challenges of using oral fluid will be discussed along with how...
Chromosomal microarray - Insights
Learn how our microarray evaluations identify, analyze, and assess clinically significant chromosomal abnormalities.
Hereditary epilepsy - Insights
Find out how we perform in-depth mutation and copy number variant analysis to determine causes of epilepsy and identify potential treatment options.
Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related...
Learn how our pediatric neuro-oncology testing includes both comprehensive MayoComplete next-generation sequencing and chromosomal microarray.
Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients'...
Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. - Insights
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely...
The Expanding Reach of the Laboratory Outreach Program - Insights
The most successful laboratory outreach programs recognize the importance of serving multiple customers. From provider to patient to healthcare consumer, the laboratory has an opportunity to serve them all with high-quality results and...
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild...